Ruffles launches new Tangy Honey Mustard behind grindhouse ad campaign
PLANO, Texas — Ruffles potato chips, one of the flagship brand’s from PepsiCo’s Frito-Lay division, announced today the launch of a new Ultimate Tangy Honey Mustard flavor potato chip and a comical marketing campaign in television, cinema and digital that is inspired by 1970s grindhouse-style action movies.
The core of the new marketing campaign includes a series of humorous movie-trailer-style ads that parody 1970s grindhouse-style action movies. Premiering with "Honey Mustard," each "film" is teased with these ads that star the brand’s newest cast of characters — whose thick mustaches and questionable acting would give any grindhouse flick a run for its money. In recent years, Ruffles has honed in on millennial-age men as its core target, starting with the development of flavors that were inspired by the real foods guys love — and this new campaign builds on that momentum.
"Ruff McThickridge and his posse bring some really hilarious personalities to the Ruffles brand. Admittedly, I would hang out with this crew," said Tony Matta, VP marketing, Frito-Lay North America. "Our fans are looking to engage in an environment like the one we’re creating in Ruff’s world — with awesome, comedic content that allows consumers to help define what Ruff and the gang become as a creative vehicle long term."
The first Ruff McThickridge spot focuses on building excitement for new Ruffles Ultimate Tangy Honey Mustard potato chips. Available on shelves nationwide this month, the new flavor adds to the brand’s Ultimate line, which was introduced last year. Ruffles Ultimate potato chips are available in a variety of flavors and have ridges twice as deep as the ridges in Ruffles Original potato chips.
Ruffles Ultimate Tangy Honey Mustard flavored potato chips are offered in a variety of sizes: a 1.875-oz. bag for a suggested retail price of $1.09; a 2.5-oz. bag for a suggested retail price of $1.49; and a 7.5-oz. bag for a suggested retail price of $4.29.
H-E-B disburses $585,000 to Texas educators
AUSTIN, Texas — H-E-B on Friday announced statewide winners of the 12th annual H-E-B Excellence in Education Awards during a banquet at Austin’s Hilton Hotel. At the ceremony, H-E-B chairman and CEO Charles Butt disbursed $585,000 in cash awards and grants and personally congratulated 23 educators, campuses, school districts and one early childhood agency for being among the best in Texas.
Former CNN anchor and current documentary producer Soledad O’Brien delivered the keynote address to a ballroom packed with hundreds of educators, elected officials, community leaders and H-E-B employees.
H-E-B launched the Excellence in Education Awards program in cooperation with the Texas Association of School Administrators in 2002 as a positive way to support public education in Texas by spotlighting best practices and celebrating the passion and creativity of Texas educators. Since its inception, H-E-B has given more than $6.5 million, making it the state’s largest monetary award program dedicated to education, the grocer reported.
FDA approves Merck cholesterol drug
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a new drug made by Merck for treating high cholesterol, the drug maker said.
Merck announced the approval of Liptruzet (ezetimibe and atorvastatin). The drug combines two preexisting cholesterol drugs: ezetimibe, which Merck markets under the brand name Zetia, and atorvastatin, which Pfizer markets under the name Lipitor. Both drugs are available as generics, but because Liptruzet is a novel combination of them, it required FDA approval as a new drug.
"A significant percentage of patients are unable to lower their [low-density lipoprotein] cholesterol to recommended levels despite treatment," Baylor College of Medicine professor Peter Jones said. "Along with a healthy diet, Liptruzet is an effective new lipid-lowering treatment option that may help address this unmet need as the complementary actions of its components can provide significant additional LDL lowering beyond atorvastatin therapy alone."